Lilly Centre for Clinical Pharmacology is a fully owned subsidiary of Eli Lilly and Company (Lilly). Our parent company, Lilly, is a global healthcare leader that unites caring with discovery to make life better for people around the world. Lilly was founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Lilly Centre for Clinical Pharmacology was established (as Lilly-NUS Centre for Clinical Pharmacology Pte Ltd) on the National University of Singapore campus in 1997 and moved to its current location in Biopolis in 2018. At the heart of LCCP is a world-class Clinical Research Unit, with 49 beds, where healthy subjects and patients participate in clinical trials of new drugs that we hope will become new medicines for treating currently unmet medical needs. We perform studies in all Lilly’s areas of interest – Diabetes, Neuroscience, Oncology, Autoimmune Disease, and have performed 169 studies over 22 years, including 20 First Human Dose studies, where new drugs have been given to people for the first time.
LCCP also hosts drug development scientists working on global teams developing new medicines for diabetes, neuroscience, cancer and inflammatory diseases such as rheumatoid arthritis. Over the years, many Lilly global drug development teams have been led by LCCP scientists.